Congress materials page

The information on this page pertains to select congresses, congress materials, and therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, or therapeutic and disease areas. Congress materials may include information for which the product is not approved for, and/or is inconsistent with the product uses described in the Prescribing Information. UroGen does not suggest or recommend the use of UroGen products in any manner other than as described in the Prescribing Information.

Filters

FILTER BY:

Reset


Product


Congresses


Year

Thumbnail of first page of 2026 AUA slides presented by Dr. Schoenberg

AUA | May 2026

Presentation
Dr. Schoenberg

Treatment With UGN-102 in Patients With Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Data From the Phase 3 ENVISION Trial

Thumbnail of first page of 2026 ASCO poster presented by Dr. Prasad

ASCO | May 2026

Poster
Dr. Prasad

Utopia: A Phase 3 Trial Of UGN-103, An Intravesical Mitomycin Reverse Thermal Hydrogel For Treatment Of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Thumbnail of first page of 2026 ASCO presentation presented by Dr. Talwar

ASCO | May 2026

Poster
Dr. Talwar

Patient Experiences With UGN-102 For Recurrent Low-Grade Intermediate-Risk Non Muscle Invasive Bladder Cancer (LG-IR-NMIBC): Insights For Shared Decision-Making

Thumbnail of first page of 2026 AUA poster presented by Dr. Shore

AUA | May 2026

Poster
Dr. Shore

Duration Of Response To UGN-102 By Age At Baseline Across 3 Clinical Trials In Patients With Recurrent Low-Grade Intermediate-Risk Bladder Cancer

Thumbnail of 2026 ASCO GU poster presented by Dr. Talwar

ASCO GU | Feb 2026

Poster
Dr. Talwar

Patient Experiences With UGN-102 For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC): Insights For Shared Decision-Making

Thumbnail of 2026 ASCO GU poster presented by Dr. Huang

ASCO GU | Feb 2026

Poster
Dr. Huang

UGN-102 Achieves Durable Responses Across EORTC Recurrence Score Groups In Adults With Recurrent Low-Grade Intermediate-Risk NMIBC (ENVISION Trial)

Thumbnail of 2025 AUA poster presented by Dr. Hu

AUA | Apr 2025

Poster
Dr. Hu

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel

Thumbnail of 2025 AUA poster presented by Dr. Shore

AUA | Apr 2025

Poster
Dr. Shore

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Long-Term Outcomes of the OPTIMA II Study

Thumbnail of 2025 AUA poster presented by Dr. Peyton

AUA | Apr 2025

Poster
Dr. Peyton

Patient-Reported Outcomes Following Treatment of Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer With UGN-102

Thumbnail of 2025 ASCO poster presented by Dr. Prasad

ASCO | May 2025

Poster
Dr. Prasad

Duration of Response (DoR) Following Treatment With UGN-102 in Patients With Recurrent, Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer: 18-Month DoR Data From the Phase 3 ENVISION Trial

Thumbnail of 2025 AUA poster presented by Dr. Peyton

AUA | Apr 2025

Poster
Dr. Peyton

Psychometric Validaton of a Quality of Life Scale in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Thumbnail of 2025 ASCO poster presented by Dr. Sfakianos

ASCO | May 2025

Poster
Dr. Sfakianos

Impact of Tumor Burden or Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer on Response to Treatment With UGN-102: A Substudy of the Phase 3 ENVISION Trial

Thumbnail of 2025 ASCO GU poster presented by Dr. Prasad

ASCO GU | Feb 2025

Poster
Dr. Prasad

Impact of Tumor Burden and Focality in Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer on Response to Treatment With UGN-102: A Subanalysis of the Phase 3 ENVISION Trial

Thumbnail of 2025 ASCO GU poster presented by Dr. Prasad

ASCO GU | Feb 2025

Poster
Dr. Prasad

Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Results of the Phase 3 ENVISION and ATLAS Studies

Thumbnail of 2024 SUO poster presented by Dr. Hu

SUO | Dec 2024

Poster
Dr. Hu

Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma (LG-UTUC) With UGN-101, a Mitomycin Reverse Thermal Gel

Thumbnail of 2024 SUO poster presented by Dr. Morris

SUO | Dec 2024

Poster
Dr. Morris

Home Instillation of UGN-102 for Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3B Trial

Thumbnail of 2024 SUO poster presented by Dr. Prasad

SUO | Dec 2024

Poster
Dr. Prasad

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Thumbnail of 2024 BCANTT poster presented by Dr. Schoenberg

BCANTT | Aug 2024

Poster
Dr. Schoenberg

Phase 3 ENVISION Trial: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (LG-IR-NMIBC) (NCT05243550)

Thumbnail of section of 2025 ASCO poster presented by Dr. Feldman

ASCO | May 2025

Poster
Dr. Feldman

The uTRACT Registry: A Single-Arm, Multicenter, Prospective and Retrospective Registry Study to Evaluate the Real-World Use of UGN-101 in Participants With Upper Tract Urothelial Carcinoma (UTUC) in the United States

Browse through UroGen scientific presentations.

Use the filters to search by the product, congress, and year you are interested in.

No results with current filters

Modify your selections to discover more content